Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.686 EUR | +6.66% | +3.60% | +41.76% |
05-21 | Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting | CI |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Sales 2024 * | 239M 22.63M 20.83M 30.88M | Sales 2025 * | 343M 32.41M 29.84M 44.23M | Capitalization | 2.66B 251M 232M 343M |
---|---|---|---|---|---|
Net income 2024 * | -735M -69.53M -64.01M -94.88M | Net income 2025 * | -712M -67.35M -62.01M -91.91M | EV / Sales 2024 * | 13.1 x |
Net Debt 2024 * | 474M 44.84M 41.28M 61.19M | Net Debt 2025 * | 733M 69.37M 63.87M 94.67M | EV / Sales 2025 * | 9.9 x |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-4.33
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 week | +7.15% | ||
Current month | +50.57% | ||
1 month | +60.26% | ||
3 months | +31.27% | ||
6 months | +65.89% | ||
Current year | +51.19% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change |
---|---|---|
24-05-28 | 3.686 | +6.66% |
24-05-27 | 3.456 | -3.25% |
24-05-24 | 3.572 | -4.13% |
24-05-23 | 3.726 | +2.87% |
24-05-22 | 3.622 | +5.29% |
Real-time BOERSE MUENCHEN, May 28, 2024 at 03:43 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- HNSA Stock
- 24H Stock